Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion type Assertion NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_head.
- NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion description "[Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treatment of breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_provenance.
- NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion evidence source_evidence_literature NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_provenance.
- NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion SIO_000772 25849870 NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_provenance.
- NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion wasDerivedFrom befree-2016 NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_provenance.
- NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_assertion wasGeneratedBy ECO_0000203 NP1276385.RAAGzpTeFzXGxjfY92BoSzjvTmhZh8N_AgLyqSx5GHcPM130_provenance.